GLP-1 and urological health: separating signal from hype
Quick answer
The video addresses real-world home reconstitution of compounded tirzepatide and semaglutide, which are lyophilized peptides requiring mixing with bacteriostatic water before subcutaneous injection. The creator demonstrates a 1 mL diluent to powder ratio yielding 0.1 mL dose increments, but this calculation is only valid for that specific reconstitution volume and assumes complete, uniform dissolution. FDA safety alerts issued in 2023 and 2024 identified compounded GLP-1 dosing errors as a growing patient safety concern, particularly when reconstitution volumes differ from assumed values or when mg and mL are confused.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @socalurologyinstitute actually say?
A urologist at SoCal Urology Institute posted a reply to a viewer question about mixing compounded GLP-1 medications at home. He walked through the basic arithmetic of diluting a lyophilized peptide vial with bacteriostatic water, using two examples: a 30 mg tirzepatide vial and a 2 mg semaglutide vial. His core claim was simple: "if you put in a CC of bacteriostatic water, each 0.1 will be 3 milligrams" for the 30 mg vial. He was trying to explain the 1:10 ratio that emerges when you add 1 mL of diluent to a powder and draw doses in 0.1 mL increments. The video is clearly a response to real patients who are self-injecting compounded peptides purchased online without professional guidance.
This is a real public health situation. Compounded semaglutide and tirzepatide have exploded in use since FDA shortage designations opened the door for 503A and 503B compounders. People are absolutely out there with vials and syringes, guessing at math.
Does the science back this up?
The dilution math itself is correct in principle, but the framing strips out everything that actually matters. Yes, adding 1 mL of bacteriostatic water to a dry powder and drawing 0.1 mL increments divides the total mass by 10. That is basic pharmaceutical arithmetic, not a controversial claim.
The problem is that this framing assumes the powder dissolved completely and uniformly, that the vial actually contains what the label says, and that the person at home has the sterile technique and equipment to execute this safely. None of those assumptions are safe to make. A 2023 analysis published by the U.S. Pharmacopeia found significant variability in peptide content among compounded GLP-1 preparations tested from online sources. Separately, the FDA issued multiple warnings in 2023 and 2024 about dosing errors with compounded semaglutide, specifically because patients were confusing mg and mL, or miscalculating after non-standard reconstitution volumes. The math he presents only works cleanly if you add exactly 1 mL. Change that volume and everything shifts.
What did they get wrong (or right)?
He got the core ratio right. If you add 1 mL to 30 mg, each 0.1 mL is 3 mg. That arithmetic holds. Credit where it is due.
But here is where it breaks down. He says "bacteria static water" twice, which is a minor verbal slip, but more importantly he presents one reconstitution volume as if it is the only one. Many compounders and prescribers use 2 mL, 3 mL, or other volumes depending on the peptide concentration and the dosing protocol. A patient who watches this video, then reconstitutes with 2 mL instead of 1 mL, and follows his math, will inject twice the dose they intended. That is not a hypothetical. The FDA's MedWatch database contains reports of exactly this error pattern. He also does not mention that compounded tirzepatide base (not salt form) has different stability and absorption characteristics than the brand-name formulation. Calling it "30 milligrams of tirzepatide" as if it is a uniform product glosses over real quality variation between compounders.
- The 1 mL reconstitution assumption is not universal and he does not say so.
- He gives no guidance on sterile technique, needle gauge, or injection site.
- He does not distinguish between compounded and FDA-approved formulations.
What should you actually know?
If you are reconstituting a compounded GLP-1 at home, the single most important thing is not the ratio. It is knowing exactly how much diluent you are adding and matching your dose calculation to that specific volume. Every calculation resets with every reconstitution volume change.
The FDA issued a safety communication in May 2024 specifically about compounded semaglutide dosing errors, noting that some products were labeled in units that patients misread as milligrams. Tirzepatide compounding had its own back-and-forth: the FDA removed tirzepatide from the shortage list in late 2024, which raised questions about the legality of continued compounding. If you are using compounded versions, ask your prescriber for written reconstitution instructions tied to the exact vial and diluent volume you have, not a general ratio from a TikTok video. A telehealth provider or pharmacist can walk through this with you for your specific product. General math tutorials, even accurate ones, are not a substitute for product-specific guidance.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 and urological health: separating signal from hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
GLP-1 and urological health: separating signal from hype should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The video addresses real-world home reconstitution of compounded tirzepatide and semaglutide, which are lyophilized peptides requiring mixing with bacteriostatic water before subcutaneous injection.
FormBlends verdict
The video addresses real-world home reconstitution of compounded tirzepatide and semaglutide, which are lyophilized peptides requiring mixing with bacteriostatic water before subcutaneous injection. The creator demonstrates a 1 mL diluent to powder ratio yielding 0.1 mL dose increments, but this calculation is only valid for that specific reconstitution volume and assumes complete, uniform dissolution. FDA safety alerts issued in 2023 and 2024 identified compounded GLP-1 dosing errors as a growing patient safety concern, particularly when reconstitution volumes differ from assumed values or when mg and mL are confused.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video addresses real-world home reconstitution of compounded tirzepatide and semaglutide, which are lyophilized peptides requiring mixing with bacteriostatic water before subcutaneous injection. The creator demonstrates a 1 mL diluent to powder ratio yielding 0.1 mL dose increments, but this calculation is only valid for that specific reconstitution volume and assumes complete, uniform dissolution. FDA safety alerts issued in 2023 and 2024 identified compounded GLP-1 dosing errors as a growing patient safety concern, particularly when reconstitution volumes differ from assumed values or when mg and mL are confused.
- The 1 mL reconstitution math is only valid if you use exactly 1 mL of diluent. Change that volume and every dose calculation changes with it.
- FDA issued a May 2024 safety communication specifically about compounded semaglutide dosing errors, many involving confusion between mg and mL or non-standard reconstitution volumes.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The 1 mL reconstitution math is only valid if you use exactly 1 mL of diluent. Change that volume and every dose calculation changes with it.
- FDA issued a May 2024 safety communication specifically about compounded semaglutide dosing errors, many involving confusion between mg and mL or non-standard reconstitution volumes.
- Compounded tirzepatide and semaglutide are not equivalent to brand-name Mounjaro, Zepbound, Ozempic, or Wegovy. Quality, concentration, and formulation vary by compounder.
- The FDA removed tirzepatide from its drug shortage list in late 2024, which affects the legal basis for 503A compounders to continue producing it.
- A U.S. Pharmacopeia analysis found meaningful content variability in compounded peptide preparations, meaning the labeled dose may not reflect actual peptide content.
- Anyone using a compounded GLP-1 should get written reconstitution instructions specific to their vial, their diluent volume, and their prescribed dose from a licensed prescriber or pharmacist, not from a general ratio tutorial.
- Bacteriostatic water is the correct diluent for most compounded GLP-1 peptides, but sterile technique, proper needle use, and cold storage are equally important factors this video did not address.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr Gary Bellman | SoCalUrology · TikTok creator
25.5K views on this video
Replying to @Mary Sicard #glp1 #glp1community
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr Gary Bellman | SoCalUrology, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.